A prophylactic low dose has also been indicated for patients with bronchiectasis (not associated with cystic fibrosis) due to the reduction in Th17 cells and IL-17 in peripheral blood, as well as improvements in PaCo2 and FEV1, demonstrating a possible role in the regulatory balance of helper T cells [68]. This evidence concerns the gene IL17A and bronchiectasis.